Molecular Tests Can Help to Reduce Repeated Prostate Biopsies.

The article indicates that molecular tests, such as ConfirmMDx from MDxHealth, may enable the advent of personalized medicine in prostate cancer, which could reduce the cost of care through evidence-based, tailored approaches for individual care management. Topics discussed include health plans considering guideline development to use a negative predicative value test. Also mentioned is the view that patients and providers should welcome the promise of a molecular epigenetic test.